REGENXBIO

REGENXBIO will host a conference call on November 5th to discuss third quarter 2026 financial results and operational highlights. Learn more: ir.regenxbio.com/news-releas… $RGNX

As we approach anticipated Phase 3 topline data from our sura-vec program, we were pleased to bring together leading retina specialists to discuss the evolving treatment landscape. Learn more about the program and hear their insights in the webcast: regenxbio.gcs-web.com/events… $RGNX

Our team had a great time in Washington, D.C. at the @ChildrensNatl Foundation’s Race for Every Child! We always look forward to participating in this inspiring local event and supporting Children’s National in its mission to elevate pediatric care, one child at a time.

We always enjoy attending @CureDuchenne's workshops. Thank you to CureDuchenne for hosting a great meeting in Indianapolis, where families had the opportunity to connect, share experiences, access valuable resources, and hear the latest updates on Duchenne research.

It was a great weekend in New Orleans! #AAO2026 showcased the progress being made in eye care. We're proud to be leading the translation of innovative science into potential new therapies that could transform how physicians approach sustained vision outcomes for their patients.

Join us for an investor event focused on sura-vec in wet AMD, ahead of topline pivotal data anticipated in Q4 2026. Hear from REGENXBIO and leading experts as we discuss the clinical program and evolving wet AMD treatment landscape. Learn more: ir.regenxbio.com/news-releas… $RGNX

On #WorldSightDay, we recognize the role vision plays in how we experience the world and the impact when it is threatened, which is why we’re advancing new approaches for retinal diseases, driven by the potential to preserve sight and make a meaningful difference for patients.

We were pleased to attend @alliancerm's #CGMesa26. REGENXBIO CEO Curran Simpson highlighted our differentiated approach to developing one-time treatments for patients and joined fellow industry leaders to discuss safety, access and manufacturing.

That’s a wrap on #WMS2026 in Hiroshima! We’re leaving this year’s @WorldMuscleSoc meeting inspired by the shared commitment to advancing meaningful progress for people living with neuromuscular diseases.

October is Blindness Awareness Month, an opportunity to recognize the impact of vision loss and the need for continued progress in vision health. We’re proud to be advancing investigational gene therapies with the potential to redefine how retinal diseases are treated.

This week, we welcomed Marissa Penrod, Duchenne mom, advocate and founder of @TeamJosephInfo, her son Joseph, Dorene Pulgini of Team Joseph, and two caregivers for a special World Duchenne Awareness Day event. We’re grateful for their time and openness.

Thank you @CureDuchenne for another great workshop, this time in San Diego. We appreciate everyone who shared their perspectives and look forward to continuing to work together in support of boys living with Duchenne and their families.

At our recent all-company meeting, we recognized Janet Yu as our CEO Award winner! Janet is a key member of our Regulatory team whose expertise, collaboration, and dedication are helping advance our programs and our mission for patients. Congratulations, Janet!

Our team is at the Retina Society Annual Scientific Meeting, where investigator Dr. Nikolas London presented positive 3-year data from the Phase II ALTITUDE study of investigational sura-vec in diabetic retinopathy. Learn more: ir.regenxbio.com/news-releas…

Last week, we hosted our fifth annual REGENXBIO Science Showcase, bringing teams together to share, learn, and collaborate. The event highlighted the depth of expertise driving our mission forward. Thank you to our team for your curiosity and dedication!

Thank you @JettFoundation for bringing the Duchenne community together for this year's World Duchenne Awareness Day Luncheon. It was great to spend time with patients, families, advocates and fellow partners who share a commitment to improving lives of those affected by Duchenne.

REGENXBIO will participate in upcoming investor conferences. Learn more: ir.regenxbio.com/news-releas… $RGNX

This World Duchenne Awareness Day, we join the global Duchenne community in recognizing that access changes lives. At REGENXBIO, we're proud to be working to advance an investigational gene therapy for Duchenne and help build a future with more possibilities for patients.

This Labor Day, we're celebrating the people behind the science. Every milestone we reach is made possible by our amazing REGENXBIO team. Thank you for the work you do each day to help bring innovative treatments to patients with serious diseases.

This #NewbornScreeningAwarenessMonth, we celebrate the tremendous progress that's been made in newborn screening and the lives that have been changed through early detection. Together, we can help give more children the best possible start.